Policy· August 31, 2026 · 16 min read
CMS Part D 340B Repository: Voluntary Files Do Not Replace Prescriber Math
By Ran Chen#340B#Medicare Part D#IRA Negotiation
Topic
IRA Negotiation
Medicare drug price negotiation, selected-drug lists, maximum fair price, and downstream lifecycle planning.
Policy· August 23, 2026 · 16 min read
CMS-10110 Turns Quarterly ASP Into a Part B MFP Compliance Feed: Comments Oct 20
By Ran Chen#CMS#ASP#Medicare Part B
Policy· August 20, 2026 · 19 min read
CMS-4215-P Comment Docket: Manufacturers and Hospitals Clash on IRA Rules
By Ran Chen#IRA Negotiation#Policy#Payer Policy
Policy· August 19, 2026 · 18 min read
CMS Bona Fide Marketing Rule: What the D.C. Circuit Teva Ruling Actually Revived
By Ran Chen#Policy#IRA Negotiation#Medicare Part D
Policy· August 9, 2026 · 18 min read
340B Rebate-Model Ruling: D.C. Circuit Puts HHS in the Driver's Seat (2026)
By Ran Chen#340B#Drug Pricing#Payer Policy
Policy· June 30, 2026 · 17 min read
IRA Medicare Drug Negotiation Proposed Rule: Market-Access Analysis
By Ran Chen#IRA Negotiation#CMS#Market Access
Generics· June 23, 2026 · 17 min read
Eliquis Generic: Why US Entry is Delayed to April 2028 Despite IRA Cuts
By Ran Chen#Generic Entry#FDA Approval#Orange Book
Policy· June 21, 2026 · 7 min read
Sitagliptin's May 2026 Generic Launch and Januvia's IRA MFP Termination
Pricing & Access· June 10, 2026 · 10 min read
PD-1/PD-L1 checkpoint inhibitor access landscape in 2026
Policy· June 10, 2026 · 8 min read
The 2026–2032 patent cliff by the numbers: 11,000 patents, $200 billion at risk
By Ran Chen#Orange Book#Generic Entry#Biosimilars